The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
J. Randolph Hecht
Research Funding - Amgen
Allen Lee Cohn
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Mansoor N. Saleh
No relevant relationships to disclose
Bilal Piperdi
Consultant or Advisory Role - Amgen
Vivian Jean M. Cline-Burkhardt
No relevant relationships to disclose
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen